No comments yet. Be the first to say something!
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The Periodic Benefit-Risk Evaluation Report (PBRER/PSUR) — the periodic post-approval safety and benefit-risk review.
Why it exists. After approval, ICH E2C(R2) requires sponsors to periodically re-evaluate a marketed drug's cumulative benefit-risk balance using worldwide data. It is the ongoing evidence that a drug's benefits still outweigh its risks in real use.
How it is produced here. It is a pharmacovigilance ('drug safety watch') document: it gathers and interprets the simulated safety data on the fixed schedule regulators expect once a drug enters development or the market.
Format & governing standard. —
| Field | Value |
|---|---|
| Document ID | PSUR-001 |
| Version | 1.0 (planned structure) |
| Status | Final (portfolio) |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| Standard(s) | ICH E2C(R2) (PBRER) · GVP Module VII · 21 CFR 314.80 |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]The PBRER is a post-authorization periodic report; GLPI-103 is pre-approval, so this document defines the structure and planned content of the first PBRER to be produced after marketing authorization, with placeholder pre-approval content. Cumulative figures trace to the clinical program (CSR-301).
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-30 | Pharmacovigilance | Initial PBRER structure / plan |
This PBRER will provide a comprehensive, evaluated benefit-risk assessment of GLPI-103 at defined intervals after authorization (typically 6-monthly until 2 years post-launch, then annually/per the EU reference-date list), per ICH E2C(R2) and GVP Module VII.
To be populated post-authorization (countries, dates, indications, dose forms). Currently investigational [MOCK].
To be populated (label changes, DHPCs, restrictions). None to date.
Tracks changes to the Company Core Safety Information (CCSI)/labeling.
Patient exposure from clinical trials (cumulative ≈1,220 subjects) plus, post-launch, estimated patient exposure from sales/prescription data, by region, formulation (IV/oral), age, and sex.
Cumulative and interval summary tabulations of serious adverse events (clinical trials) and, post-launch, of spontaneous and solicited reports by MedDRA SOC/PT.
Confirmed efficacy: superiority over oral semaglutide on HbA1c (IV −0.68%, Oral −0.34%; CSR-301) with substantial weight reduction and high responder rates; real-world effectiveness to be added post-launch.
After approval, the PBRER periodically re-asks the approval question using real-world data: given everything now known, do the benefits still outweigh the risks? It is how a drug's safety is kept under review for its whole life on the market.
The benefit-risk of GLPI-103 in adults with T2DM inadequately controlled on metformin remains favourable: clinically meaningful, robust glycaemic and weight benefit against a class-consistent, monitorable, and largely manageable risk profile (M2.5.6), with the principal gastrointestinal tolerability trade-off mitigated by titration.
No new risk-minimization measures are warranted at the current (pre-authorization) stage. Post-launch, conclusions and any label/RMP changes will be presented here, with the next data-lock point and submission timeline per the reference-date list.